Title:
MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH ENHANCED INTRAOCULAR NEOVASCULARIZATION AND/OR INTRAOCULAR VASCULAR PERMEABILITY
Document Type and Number:
WIPO Patent Application WO/2019/151470
Kind Code:
A1
Abstract:
Provided is a medicine for preventing or treating an ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability. The present inventors have made studies on medicines for preventing or treating ophthalmic diseases associated with enhanced intraocular neovascularization and/or intraocular vascular permeability. As a result, it is confirmed that a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor has an activity to prevent intraocular neovascularization and an activity to prevent intraocular vascular permeability, and the present invention is accomplished. A compound according to the present invention, which is a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor or a pharmaceutically acceptable salt thereof has an activity to prevent intraocular neovascularization and intraocular vascular permeability, and can be used as a prophylactic and/or therapeutic agent for exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, neovascular glaucoma or the like.
More Like This:
Inventors:
HARA HIDEAKI (JP)
NARUMIYA SHUH (JP)
AOKI TOMOHIRO (JP)
ARAMORI ICHIRO (JP)
YAMAMOTO RIE (JP)
NARUMIYA SHUH (JP)
AOKI TOMOHIRO (JP)
ARAMORI ICHIRO (JP)
YAMAMOTO RIE (JP)
Application Number:
PCT/JP2019/003573
Publication Date:
August 08, 2019
Filing Date:
February 01, 2019
Export Citation:
Assignee:
UNIV KYOTO (JP)
ASTELLAS PHARMA INC (JP)
ASTELLAS PHARMA INC (JP)
International Classes:
A61K45/00; A61K31/135; A61K31/397; A61K31/403; A61K31/4245; A61K31/426; A61K31/496; A61P9/10; A61P27/02
Domestic Patent References:
| WO2008063932A2 | 2008-05-29 | |||
| WO2011087066A1 | 2011-07-21 | |||
| WO2012105610A1 | 2012-08-09 | |||
| WO2008055072A2 | 2008-05-08 | |||
| WO2007053447A2 | 2007-05-10 | |||
| WO2006013948A1 | 2006-02-09 | |||
| WO2007089018A1 | 2007-08-09 | |||
| WO2007091570A1 | 2007-08-16 | |||
| WO2009017219A1 | 2009-02-05 | |||
| WO2006094705A1 | 2006-09-14 | |||
| WO2008152149A1 | 2008-12-18 | |||
| WO2012145236A1 | 2012-10-26 | |||
| WO2011066184A1 | 2011-06-03 | |||
| WO2012071186A1 | 2012-05-31 | |||
| WO2012071184A1 | 2012-05-31 | |||
| WO2011050054A2 | 2011-04-28 | |||
| WO2011066179A1 | 2011-06-03 | |||
| WO2012074921A1 | 2012-06-07 | |||
| WO2012142268A1 | 2012-10-18 | |||
| WO2014130565A1 | 2014-08-28 | |||
| WO2014078209A1 | 2014-05-22 | |||
| WO2014078208A1 | 2014-05-22 | |||
| WO2014071342A1 | 2014-05-08 | |||
| WO2005002559A2 | 2005-01-13 | |||
| WO2007116866A1 | 2007-10-18 | |||
| WO2010064707A1 | 2010-06-10 | |||
| WO2014175287A1 | 2014-10-30 |
Foreign References:
| JP2008531632A | 2008-08-14 | |||
| JP2018016911A | 2018-02-01 | |||
| US20110257232A1 | 2011-10-20 |
Other References:
HARA, HIDEAKI; KUSE, YOSHIKI; MASUDA, TOMOMI; TSURUMA, KAZUHIRO; SHIMAZAWARA, MASAMITSU: "Frontiers in Ocular Pharmacological Research Focusing on Retina", JAPANESE JOURNAL OF OCULAR PHARMACOLOGY, vol. 30, no. 1, 2016, pages 12 - 21, XP009522294, ISSN: 0914-1405
OMORI, K. ET AL.: "Edaravone mimics sphingosine-1- phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells", AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, vol. 293, 2007, pages C1523 - C1531, XP055294016, DOI: 10.1152/ajpcell.00524.2006
YAMAMOTO, R. ET AL.: "ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile", PLOS ONE, vol. 9, no. 10, 2014, pages e110819, XP055630609
BLANCO, R. ET AL.: "The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss", EXPERIMENTAL EYE RESEARCH, vol. 164, 2017, pages 37 - 45, XP085205920, DOI: 10.1016/j.exer.2017.08.005
JUNG, B. ET AL.: "Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development", DEVELOPMENTAL CELL, vol. 23, no. 3, 2012, pages 600 - 610, XP055630611
SCIENTIFIC REPORTS, vol. 7, 2017, pages 43509
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1206123-37-6
PLOS ONE, vol. 9, no. 10, 2014, pages ell0819
BRITISH JOURNAL OF PHARMACOLOGY, vol. 173, 2016, pages 1778 - 1792
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 337, 2011, pages 547 - 556
ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, 2014, pages 1313 - 1317
See also references of EP 3747471A4
OMORI, K. ET AL.: "Edaravone mimics sphingosine-1- phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells", AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, vol. 293, 2007, pages C1523 - C1531, XP055294016, DOI: 10.1152/ajpcell.00524.2006
YAMAMOTO, R. ET AL.: "ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile", PLOS ONE, vol. 9, no. 10, 2014, pages e110819, XP055630609
BLANCO, R. ET AL.: "The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss", EXPERIMENTAL EYE RESEARCH, vol. 164, 2017, pages 37 - 45, XP085205920, DOI: 10.1016/j.exer.2017.08.005
JUNG, B. ET AL.: "Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development", DEVELOPMENTAL CELL, vol. 23, no. 3, 2012, pages 600 - 610, XP055630611
SCIENTIFIC REPORTS, vol. 7, 2017, pages 43509
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1206123-37-6
PLOS ONE, vol. 9, no. 10, 2014, pages ell0819
BRITISH JOURNAL OF PHARMACOLOGY, vol. 173, 2016, pages 1778 - 1792
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 337, 2011, pages 547 - 556
ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, 2014, pages 1313 - 1317
See also references of EP 3747471A4
Attorney, Agent or Firm:
SHOJI, Takashi et al. (JP)
Download PDF: